XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
May 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborations with Third Parties                
Total Revenues           $ 78,447 $ 227,547 $ 148,364
License for Intellectual Property                
Collaborations with Third Parties                
Total Revenues               144,400
Ongoing Regulatory and Development Activities                
Collaborations with Third Parties                
Total Revenues             1,600 4,000
Royalty Revenue From DSE                
Collaborations with Third Parties                
Total Revenues           9,900 2,800  
Collaboration Revenue                
Collaborations with Third Parties                
Total Revenues           38,400 214,582 148,364
Daiichi Sankyo Europe GmbH ("DSE") | NUSTENDI, MAA                
Collaborations with Third Parties                
Total Revenues             150,000  
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement                
Collaborations with Third Parties                
Upfront cash payment     $ 150,000          
Cash payment to the Company             150,000  
Total Revenues               $ 148,400
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Minimum                
Collaborations with Third Parties                
Percentage of royalties to be received on the net sales     15.00%          
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Maximum                
Collaborations with Third Parties                
Percentage of royalties to be received on the net sales     25.00%          
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities                
Collaborations with Third Parties                
Upfront cash payment   $ 60,000         $ 60,000  
Potential additional future payments   450,000            
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Collaboration Revenue                
Collaborations with Third Parties                
Total Revenues   $ 60,000            
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Minimum                
Collaborations with Third Parties                
Percentage of royalties to be received on the net sales   15.00%            
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Maximum                
Collaborations with Third Parties                
Percentage of royalties to be received on the net sales   30.00%            
Milestone payment, first JNDA submissions   $ 20,000            
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000            
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000            
Milestone payments related to total net sales achievements   $ 310,000            
Daiichi Sankyo Co. Ltd                
Collaborations with Third Parties                
Total Revenues           28,500    
Daiichi Sankyo Co. Ltd | Collaborative Arrangement                
Collaborations with Third Parties                
Upfront cash payment       $ 30,000        
Total Revenues           28,500    
Potential additional future payments $ 175,000              
Consideration cash payment 30,000              
Additional one time payment $ 175,000              
Remaining upfront payment           1,500    
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Minimum                
Collaborations with Third Parties                
Percentage of royalties to be received on the net sales 5.00%              
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Maximum                
Collaborations with Third Parties                
Percentage of royalties to be received on the net sales 20.00%              
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, License To Intellectual Property                
Collaborations with Third Parties                
Total Revenues           28,000    
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, Ongoing Regulatory And Development Activities                
Collaborations with Third Parties                
Total Revenues           $ 500    
Serometrix | Collaborative Arrangement                
Collaborations with Third Parties                
Upfront cash payment         $ 12,500